Logo-jpd
J parathyr dis. 2016;4(1): 3-6.
  Abstract View: 434
  PDF Download: 124

Original

Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial

Heshmatollah Shahbazian 1, Mohammad-Reza Tamadon 2, Seyed Karim Mowla 3, Shokouh Shayanpour 3*, Fatemeh Hayati 4, Melika Shojaii 5, Leila Yazdanpanah 6

1 Department of Nephrology, Golestan Hospital, Chronic Renal Failure Research Center, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
2 Department of Nephrology, Semnan University of Medical Sciences, Semnan, Iran.
3 Department of Rheumatology, Golestan Hospital, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
4 Department of Nephrology, Imam Khomeini Hospital, Chronic Renal Failure Research Center, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
5 Department of Internal Medicine, Golestan Hospital, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
6 Health Research Institute, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
*Corresponding author: Shokouh Shayanpour, Dr.shayanpour@yahoo.com

Abstract

Introduction: With decline of glomerular filtration rate (GFR), a number of metabolic bone diseases such as osteoporosis are  simultaneously caused. We evaluated the results of alendronate on bone density in patients with chronic kidney disease (CKD).

Objectives: The main aim of the study was evaluation of the changes in bone density, one year after treatment by dual energy x-ray absorptiometry technique.

Patients and Methods: We evaluated two treatment regimens on bone density of 44 patients between 18-45 years old (22 in experimental and 22 in control group) in a controlled double blind randomized trial. The experimental group was prescribed alendronate (10 mg), calcitriol (0.25 μg) and calcium carbonate (1500 mg) daily. The control group was treated with the same regimen except for alendronate.

Results: After completion of the trial, bone density decreased in all patients in the control group, but increased in the experimental group, in lumbar spine and femoral neck, 6.4% and 4.5% respectively. Alendronate was well tolerated.

Conclusion: Alendronate is safe in these patients and increases the bone density in CKD stage 1 and 2. Keywords: Alendronate; Bone density; Chronic kidney disease

Keywords: Alendronate, Bone density, Chronic kidney disease

Implication for health policy/practice/research/ medical education

In a study on 44 chronic kidney disease (CKD) patients, we found that alendronate is a safe and effective agent for treatment of osteoporosis in CKD of stages I and II.  

Please cite this paper as: Shahbazian H, Tamadon MR, Mowla SK, Shayanpour Sh, Hayati F, Shojaii M, et al. Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial. J Parathyr Dis. 2016;4(1):3-6.

 

 

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 434

Your browser does not support the canvas element.


PDF Download: 124

Your browser does not support the canvas element.

ePublished: 29 Jan 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)